Figure Legends
Figure 1 . Flow chart of the inclusion of ANCA positive EGPA
patients. ANCA=anti-neutrophil cytoplasmic antibody, EGPA=eosinophilic
granulomatosis with polyangiitis
Figure 2 . Changes in serum eosinophils (A), ANCA (B-1 and B-2),
GCs dose (C), BVAS (D), serum IgE (E), and serum IgG (F) due to
treatment of GCs or mepolizumab. ANCA=anti-neutrophil cytoplasmic
antibody, BVAS=Birmingham Vasculitis Activity Score, GCs=glucocorticoids
treatment, Mepo=mepolizumab treatment.
Authors : Yosuke Kamide, Kentaro Watai, Yuto Nakamura, Maki
Iwata, Yuma Fukutomi, Masami Taniguchi, and Kiyoshi Sekiya
Affiliations :
1 Clinical Research Center for Allergy and Rheumatology, Sagamihara
National Hospital, Sagamihara, Japan
2 Center for Immunology and Allergology, Shonan Kamakura General
Hospital, Kanagawa, Japan.
Correspondence to : Yosuke Kamide
Clinical Research Center for Allergy and Rheumatology, Sagamihara
National Hospital, Sagamihara, Japan.